p53 mutations frequently occur in low grade gliomas (WHO grade II astrocytoma) [24] and, thus, are a frequent event in the pathological progression of secondary GBM (WHO Grade IV) [25]. This evidence concerns the gene TP53 and central nervous system cancer.